References
- Fang Y, Ferrie AM, Fontaine NH, Mauro J, Balakrishnan J. Resonant waveguide grating biosensor for living cell sensing. Biophys J (2006), 91, 1925–1240.
- Williams M. Target validation. Curr Opin Pharmacol (2003), 3, 571–577.
- Fang Y, Li G, Ferrie AM. Non-invasive optical biosensor for assaying endogenous G protein-coupled receptors in adherent cells. J Pharmacol Toxicol Methods (2007), 55, 314–322.
- Fang Y, Frutos AG, Verklereen R. Label-Free Cell-Based Assays for GPCR Screening. Comb Chem High Throughput Screen (2008), 11, 357–369.
- Neves SR, Ram PT, Iyengar R. G protein pathways. Science (2002), 296, 1636–1639.
- Sun Y, McGarrigle D, Huang XY. When a G protein-coupled receptor does not couple to a G protein. Mol Biosyst (2007), 3, 849–854.
- Sun Y, Huang J, Xiang Y, Bastepe M, Juppner H, Kobilka BK, et al. Dosage-dependent switch from G protein-coupled to G protein-independent signaling by a GPCR. EMBO J (2007), 26, 53–64.
- Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature (1995), 375, 247–250.
- Mellado M, Rodriguez-Frade JM, Aragay A, del Real G, Martin AM, Vila-Coro AJ, Serrano A, Mayor F Jr, Martinez A C. The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J Immunol (1998), 161, 805–813.
- Wong M, Fish EN. RANTES and MIP-1alpha activate stats in T cells. J Biol Chem (1998), 273, 309–314.
- Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science (2005), 308, 512–517.
- Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science (2001), 294, 1307–1313.
- Luttrell LM, Roudabush FL, Choy EW, Miller WE, Field ME, Pierce KL, Lefkowitz RJ. Activation and targeting of extracellular signal-regulated kinases by beta-arrestin scaffolds. Proc Natl Acad Sci USA (2001), 98, 2449–2454.
- DeFea KA, Zalevsky J, Thoma MS, Dery O, Mullins RD, Bunnett NW. beta-arrestin-dependent endocytosis of proteinase- activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol (2000), 148, 1267–1281.
- HighTech Business Decisions. High Throughput screening 2007: New Strategies, Success Rates, and Use of Enabling Technologies. [Market Report]. (2007), 1.
- Butcher EC. Can cell systems biology rescue drug discovery? Nat Rev Drug Discov (2005), 4, 461–467.
- van der Greef J, McBurney RN. Innovation: Rescuing drug discovery: in vivo systems pathology and systems pharmacology. Nat Rev Drug Discov (2005), 4, 961–967.
- Bland JM, Altman DG. Statistical method for assessing agreement between two methods of clinical measurement. Lancet (1986), 1, 307–310.
- Drews J. Drug discovery: a historical perspective. Science (2000), 287, 1960–1964.
- Bender A, Bojanic D, Davies JW, Crisman TJ, Mikhailov D, Scheiber J, Jenkins JL, Deng Z, Hill WAG, Popov M, Jacoby E, Glick M. Which aspects of HTS are empirically correlated with downstream success? Curr Opin Drug Discovery & Dev (2008), 11, 327–337.
- Bleicher KH, Bohm HJ, Muller K, Alanine AI. Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov (2003), 2, 369–378.
- Zheng CJ, Han LY, Yap CW, Ji ZL, Cao ZW, Chen YZ. Therapeutic targets: progress of their exploration and investigation of their characteristics. Pharmacol Rev (2006), 58, 259–279.
- Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, Lefkowitz RJ. Independent b-arrestin 2 and G protein-mediated patways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA (2003), 100, 10782–10787.
- Lee PH, Gao A, van Staden C, Ly J, Salon J, Xu A, Fang Y, Verkleeren R. Evaluation of dynamic mass redistribution technology for pharmacological studies of recombinant and endogenously expressed g protein-coupled receptors. Assay Drug Dev Technol (2008), 6, 83–94.
- Schröder R, Merten N, Mathiesen JM, Martini L, Letunic AK, Krop F, et al. The C-terminal tail of CRTH2 is a key molecular determinant that constrains GalphaI- and downstream- signaling cascade activation. J Biol Chem (2009), 284, 1324–1336.